BioMarin Pharmaceutical Inc. (0HNC.L)
USD 70.03
(-2.19%)
USD 70.03
(-2.19%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 378.74 Million USD | 5.65% |
| 2022 | 358.48 Million USD | -27.11% |
| 2021 | 491.8 Million USD | 15.45% |
| 2020 | 425.98 Million USD | 3.73% |
| 2019 | 410.67 Million USD | 22.07% |
| 2018 | 336.43 Million USD | -41.64% |
| 2017 | 576.44 Million USD | 109.68% |
| 2016 | 274.9 Million USD | 3.64% |
| 2015 | 265.24 Million USD | 221.95% |
| 2014 | -217.51 Million USD | -350.63% |
| 2013 | 86.78 Million USD | -48.25% |
| 2012 | 167.69 Million USD | -44.48% |
| 2011 | 302.05 Million USD | 4.36% |
| 2010 | 289.44 Million USD | -12.27% |
| 2009 | 329.91 Million USD | 316.82% |
| 2008 | -152.15 Million USD | -155.26% |
| 2007 | 275.34 Million USD | 94.5% |
| 2006 | 141.56 Million USD | -23.96% |
| 2005 | 186.16 Million USD | -27.78% |
| 2004 | 257.76 Million USD | 7072.01% |
| 2003 | 3.59 Million USD | 114.07% |
| 2002 | -25.53 Million USD | -266.08% |
| 2001 | -6.97 Million USD | 57.58% |
| 2000 | -16.44 Million USD | 29.42% |
| 1999 | -23.3 Million USD | -150.56% |
| 1998 | -9.3 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 340.96 Million USD | 2.75% |
| 2024 Q2 | 127.49 Million USD | -62.61% |
| 2024 Q3 | -80.82 Billion USD | -157.07% |
| 2023 Q3 | 300.57 Million USD | -23.05% |
| 2023 FY | 378.74 Million USD | 5.65% |
| 2023 Q4 | 331.84 Million USD | 10.41% |
| 2023 Q1 | 503.93 Million USD | 40.57% |
| 2023 Q2 | 390.61 Million USD | -22.49% |
| 2022 Q4 | 358.48 Million USD | 11.85% |
| 2022 Q3 | 320.51 Million USD | -30.51% |
| 2022 FY | 358.48 Million USD | -27.11% |
| 2022 Q1 | 485.45 Million USD | -1.29% |
| 2022 Q2 | 461.24 Million USD | -4.99% |
| 2021 Q3 | 460.95 Million USD | 5.83% |
| 2021 Q4 | 491.8 Million USD | 6.69% |
| 2021 FY | 491.8 Million USD | 15.45% |
| 2021 Q1 | 408.81 Million USD | -4.03% |
| 2021 Q2 | 435.57 Million USD | 6.55% |
| 2020 FY | 425.98 Million USD | 3.73% |
| 2020 Q3 | 432.77 Million USD | -30.69% |
| 2020 Q1 | 376.04 Million USD | -8.43% |
| 2020 Q2 | 624.4 Million USD | 66.04% |
| 2020 Q4 | 425.98 Million USD | -1.57% |
| 2019 Q3 | 420.39 Million USD | -20.92% |
| 2019 FY | 410.67 Million USD | 22.07% |
| 2019 Q1 | 470.39 Million USD | 39.82% |
| 2019 Q2 | 531.58 Million USD | 13.01% |
| 2019 Q4 | 410.67 Million USD | -2.31% |
| 2018 Q1 | 709.01 Million USD | 23.0% |
| 2018 FY | 336.43 Million USD | -41.64% |
| 2018 Q4 | 336.43 Million USD | 5.74% |
| 2018 Q3 | 318.16 Million USD | -58.37% |
| 2018 Q2 | 764.21 Million USD | 7.78% |
| 2017 Q3 | 734.63 Million USD | 128.62% |
| 2017 Q1 | 342.69 Million USD | 24.66% |
| 2017 FY | 576.44 Million USD | 109.68% |
| 2017 Q2 | 321.34 Million USD | -6.23% |
| 2017 Q4 | 576.44 Million USD | -21.53% |
| 2016 Q1 | 397.55 Million USD | 49.88% |
| 2016 Q4 | 274.9 Million USD | 966.92% |
| 2016 FY | 274.9 Million USD | 3.64% |
| 2016 Q3 | -31.71 Million USD | -108.71% |
| 2016 Q2 | 364.13 Million USD | -8.41% |
| 2015 Q1 | -245.07 Million USD | -12.67% |
| 2015 Q2 | 220.82 Million USD | 190.1% |
| 2015 Q4 | 265.24 Million USD | -8.99% |
| 2015 FY | 265.24 Million USD | 221.95% |
| 2015 Q3 | 291.44 Million USD | 31.98% |
| 2014 Q2 | 66.15 Million USD | 205.69% |
| 2014 FY | -217.51 Million USD | -350.63% |
| 2014 Q3 | 258.87 Million USD | 291.32% |
| 2014 Q4 | -217.51 Million USD | -184.02% |
| 2014 Q1 | 21.64 Million USD | -75.06% |
| 2013 Q3 | -103.25 Million USD | -57.35% |
| 2013 Q1 | -44.53 Million USD | -126.55% |
| 2013 Q2 | -65.62 Million USD | -47.36% |
| 2013 FY | 86.78 Million USD | -48.25% |
| 2013 Q4 | 86.78 Million USD | 184.05% |
| 2012 FY | 167.69 Million USD | -44.48% |
| 2012 Q4 | 167.69 Million USD | 0.43% |
| 2012 Q1 | 265.74 Million USD | -12.02% |
| 2012 Q2 | 170.54 Million USD | -35.82% |
| 2012 Q3 | 166.97 Million USD | -2.1% |
| 2011 Q4 | 302.05 Million USD | 9.01% |
| 2011 FY | 302.05 Million USD | 4.36% |
| 2011 Q3 | 277.08 Million USD | 4.73% |
| 2011 Q1 | 286.73 Million USD | -0.93% |
| 2011 Q2 | 264.56 Million USD | -7.73% |
| 2010 Q3 | 369.54 Million USD | -3.08% |
| 2010 FY | 289.44 Million USD | -12.27% |
| 2010 Q2 | 381.3 Million USD | -1.76% |
| 2010 Q1 | 388.12 Million USD | 17.64% |
| 2010 Q4 | 289.44 Million USD | -21.68% |
| 2009 Q4 | 329.91 Million USD | 8.06% |
| 2009 FY | 329.91 Million USD | 316.82% |
| 2009 Q1 | 352.82 Million USD | 2.29% |
| 2009 Q2 | 297.03 Million USD | -15.81% |
| 2009 Q3 | 305.3 Million USD | 2.78% |
| 2008 Q4 | 344.92 Million USD | 52.61% |
| 2008 Q3 | 226.02 Million USD | -9.9% |
| 2008 Q1 | 183.37 Million USD | -33.4% |
| 2008 Q2 | 250.85 Million USD | 36.8% |
| 2008 FY | -152.15 Million USD | -155.26% |
| 2007 FY | 275.34 Million USD | 94.5% |
| 2007 Q1 | 148.9 Million USD | 5.18% |
| 2007 Q2 | 366.48 Million USD | 146.13% |
| 2007 Q3 | 279.04 Million USD | -23.86% |
| 2007 Q4 | 275.34 Million USD | -1.33% |
| 2006 Q2 | 88.02 Million USD | 65.48% |
| 2006 Q3 | 108.08 Million USD | 22.79% |
| 2006 Q1 | 53.19 Million USD | -71.43% |
| 2006 FY | 141.56 Million USD | -23.96% |
| 2006 Q4 | 141.56 Million USD | 30.97% |
| 2005 FY | 186.16 Million USD | -27.78% |
| 2005 Q3 | 169.93 Million USD | -19.46% |
| 2005 Q2 | 210.99 Million USD | 33.2% |
| 2005 Q1 | 158.41 Million USD | -38.54% |
| 2005 Q4 | 186.16 Million USD | 9.56% |
| 2004 FY | 257.76 Million USD | 7072.01% |
| 2004 Q1 | 28.8 Million USD | 701.36% |
| 2004 Q2 | 138.75 Million USD | 381.79% |
| 2004 Q3 | 235.82 Million USD | 69.96% |
| 2004 Q4 | 257.76 Million USD | 9.3% |
| 2003 Q4 | 3.59 Million USD | 105.71% |
| 2003 Q3 | -62.97 Million USD | 34.92% |
| 2003 Q2 | -96.77 Million USD | 20.24% |
| 2003 Q1 | -121.33 Million USD | -326.67% |
| 2003 FY | 3.59 Million USD | 114.07% |
| 2002 Q1 | -12.98 Million USD | -86.08% |
| 2002 FY | -25.53 Million USD | -266.08% |
| 2002 Q4 | -28.43 Million USD | 3.58% |
| 2002 Q2 | -15.86 Million USD | -22.2% |
| 2002 Q3 | -29.49 Million USD | -85.92% |
| 2001 Q4 | -6.97 Million USD | 0.19% |
| 2001 Q2 | -18.67 Million USD | 4.96% |
| 2001 Q1 | -19.64 Million USD | -19.45% |
| 2001 Q3 | -6.98 Million USD | 62.57% |
| 2001 FY | -6.97 Million USD | 57.58% |
| 2000 Q2 | -10.51 Million USD | 74.09% |
| 2000 Q3 | -16 Million USD | -52.27% |
| 2000 FY | -16.44 Million USD | 29.42% |
| 2000 Q1 | -40.57 Million USD | -74.11% |
| 2000 Q4 | -16.44 Million USD | -2.75% |
| 1999 Q3 | -32.5 Million USD | -465.17% |
| 1999 Q2 | 8.9 Million USD | 354.29% |
| 1999 Q1 | -3.5 Million USD | 0.0% |
| 1999 FY | -23.3 Million USD | -150.56% |
| 1999 Q4 | -23.3 Million USD | 28.3% |
| 1998 FY | -9.3 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 1129.095% |
| Myriad Genetics, Inc. | 88.1 Million USD | -329.907% |
| Evolus, Inc. | 63.7 Million USD | -494.506% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 64.075% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 66.922% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 1313.275% |
| uniQure N.V. | -102.95 Million USD | 467.892% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 350.787% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -1087.856% |
| bluebird bio, Inc. | 108.57 Million USD | -248.848% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 3860.778% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 76.109% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 379.725% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -91.224% |
| Dynavax Technologies Corporation | 106.63 Million USD | -255.182% |
| Editas Medicine, Inc. | -87.11 Million USD | 534.763% |
| FibroGen, Inc. | 56.76 Million USD | -567.197% |
| Geron Corporation | 14.76 Million USD | -2465.87% |
| Blueprint Medicines Corporation | 702.83 Million USD | 46.111% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 97.054% |
| Illumina, Inc. | 1.21 Billion USD | 68.802% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 432.562% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 2699.149% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -113.62% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 4300.843% |
| Adicet Bio, Inc. | -142 Million USD | 366.709% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 60.888% |
| Insmed Incorporated | 721.62 Million USD | 47.514% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 439.983% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 81.947% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -5169.904% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1229.681% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 95.401% |
| Waters Corporation | 1.96 Billion USD | 80.68% |
| Zoetis Inc. | 4.76 Billion USD | 92.046% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 98.589% |
| Biogen Inc. | 6.28 Billion USD | 93.977% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 5434.479% |
| Nektar Therapeutics | 210.24 Million USD | -80.15% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 798.076% |
| Perrigo Company plc | 3.32 Billion USD | 88.599% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 289.544% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -161.069% |
| Verastem, Inc. | -37.27 Million USD | 1116.009% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 103.96% |
| Imunon, Inc. | -4.69 Million USD | 8159.715% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -5335.475% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 17.43% |
| Homology Medicines, Inc. | 18.43 Million USD | -1954.282% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 1497.594% |
| OPKO Health, Inc. | 230.68 Million USD | -64.185% |
| Exelixis, Inc. | -73.05 Million USD | 618.478% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 72.572% |
| TG Therapeutics, Inc. | 17.86 Million USD | -2020.412% |
| Incyte Corporation | -3.17 Billion USD | 111.929% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 50.542% |